Prenetics Global (NASDAQ:PRE) Issues Earnings Results, Beats Expectations By $0.22 EPS

Prenetics Global (NASDAQ:PRE) announced its quarterly earnings data on Wednesday. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.22, Zacks reports. Prenetics Global had a negative net margin of 60.70% and a negative return on equity of 30.12%.

Here are the key takeaways from Prenetics Global’s conference call:

• IM8 drove an explosive 2025, pushing Prenetics to record revenue of $92.4M and reaching a $120M annualized run rate for IM8 within its first year, with IM8 contributing $60.1M for the full year and $27.4M in Q4.
• Management completed strategic divestitures (ACT Genomics, Europa, 35% stake in Insighta) and now reports ~$171.1M in adjusted liquid assets with zero debt, strengthening the balance sheet to support IM8’s global expansion.
• Unit economics are strong—projected blended LTV:CAC of ~3x, a payback period of ~3.4 months, and a shift to quarterly subscriptions has doubled blended AOV to ~$233 and produced an ~80% new-customer subscription rate, improving cash flow and retention.
• Prenetics reaffirmed 2026 guidance of $180M–$200M for IM8 with ~60% gross margin, expects a 2026 adjusted EBITDA loss of ~$16M–$20M while investing in growth, and reiterated a clear path to adjusted EBITDA profitability by Q4 2027.
• External validation and upside potential — Roth Capital and Sidoti initiated buy coverage (12‑month targets $36 and $30) and management plans two new SKUs by Q4 2026 (not included in 2026 guidance), providing potential incremental growth.

Prenetics Global Price Performance

Shares of NASDAQ:PRE traded down $2.61 during trading hours on Wednesday, hitting $19.13. The company’s stock had a trading volume of 97,207 shares, compared to its average volume of 253,398. The firm’s fifty day moving average price is $17.57 and its 200 day moving average price is $13.84. Prenetics Global has a 52 week low of $3.09 and a 52 week high of $22.86. The company has a market capitalization of $321.96 million, a price-to-earnings ratio of -9.48 and a beta of 0.35.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Roth Mkm initiated coverage on Prenetics Global in a research note on Wednesday, February 11th. They issued a “buy” rating and a $36.00 target price on the stock. Cantor Fitzgerald upped their price target on shares of Prenetics Global from $26.00 to $32.00 and gave the stock an “overweight” rating in a report on Wednesday, October 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research note on Thursday, January 22nd. Finally, Wall Street Zen cut shares of Prenetics Global from a “buy” rating to a “hold” rating in a research report on Monday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $34.00.

Institutional Trading of Prenetics Global

Hedge funds have recently bought and sold shares of the stock. Boothbay Fund Management LLC purchased a new position in shares of Prenetics Global in the 4th quarter valued at $241,000. Jump Financial LLC purchased a new stake in shares of Prenetics Global during the 4th quarter worth $268,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Prenetics Global during the 4th quarter worth $307,000. Marshall Wace LLP bought a new stake in Prenetics Global during the fourth quarter valued at about $788,000. Finally, Hudson Bay Capital Management LP purchased a new position in Prenetics Global in the fourth quarter valued at about $296,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.